You are here » Home » Companies » Company Overview » Combat Drugs Ltd

Combat Drugs Ltd.

BSE: 524752 Sector: Health care
NSE: N.A. ISIN Code: INE643N01012
BSE LIVE 13:56 | 06 Dec 8.88 0
(0.00%)
OPEN

8.88

HIGH

8.88

LOW

8.88

NSE LIVE 05:30 | 01 Jan Stock Is Not Traded.
OPEN 8.88
PREVIOUS CLOSE 8.88
VOLUME 325
52-Week high 8.88
52-Week low 3.49
P/E
Mkt Cap.(Rs cr) 7.10
Buy Price 8.88
Buy Qty 2425.00
Sell Price 0.00
Sell Qty 0.00
OPEN 8.88
CLOSE 8.88
VOLUME 325
52-Week high 8.88
52-Week low 3.49
P/E
Mkt Cap.(Rs cr) 7.10
Buy Price 8.88
Buy Qty 2425.00
Sell Price 0.00
Sell Qty 0.00

Combat Drugs Ltd. (COMBATDRUGS) - Company History

Incorporated as a private limited company in Sep.'86, Combat Drugs (CDL) was converted into a public limited company in Jun.'92. The company was promoted by Suchit Mohan Lal and Ajay Karan. CDL came out with a public issue of 23.23 lac equity shares at par aggregating Rs 2.32 cr in Nov.'94. The proceeds of the issue were utilised to part-finance a Rs 3.25-cr project to expand the existing manufacturing facilities for pharmaceutical formulations and to diversify into the manufacture of sterile powder injectables. CDL started commercial production in Jul.'87 on a loan-licence basis. The company acquired a full-fledged manufacturing unit located at Balanagar, Hyderabad, on lease from Fairchild Laboratories and commenced commercial production in Aug.'88. In Jul.'92 the manufacturing activities were shifted to the present leased premises at Kushaiguda, Hyderabad. In this unit various pharmaceutical formulations such as tablets, capsules and liquids are being manufactured. The product range of CDL comprises vital anti-bacterial drugs, antibiotic drugs, anti-inflammatory drugs, haematenic drugs and protein tonic. CDL has developed in-house technology for the manufacture of dispersible and sustained release formulations. The company is exploring the possibilities of exporting its products to Nigeria and West Indies. During the year 1995-96, the expansion programme undertaken by the company was successfully completed and the unit at Yellampet has become operational. During 1996-97, the company has expanded its operations to new areas. It has expanded its product range by introduction of Liquid Orals. The product "HB 2" has been well accepted in the market. The company has also filled its application for obtaining the (c)GMP and WHO GMP Certificate. During the year 1998-99, the Company initiated steps to diversify into information technology. The Company is in the process of taking over the business of M/s. Softech Institute of Information Technology & Software Development, which would function as the Infotech Division of the Company. The Company also proposes to change its name to "Combat Drugs and Softech Limited" so as to justify both the activities of Pharmaceutical Formulations and Information Technology.

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard